网站首页-南京科默生物医药有限公司

scroll down

About Us

Nanjing Caremo Biomedical Co., Ltd. was founded in June 2020 in Nanjing by Dr.Zhang Xiaoqing. Caremo is committed to provide one-stop and customizable pharmaceutical R&D solutions for global biotech companies and pharmaceutical companies. Our services contain compound activity screening, cell biology, pharmacology and pharmacodynamics evaluation, pharmacokinetics evaluation, drug safety evaluation(Non-GLP), CMC service, clinical research, customizable development service and new drug projects investment.

2026-02-10

The 2025 Annual Commendation Ceremony of Comer Pharmaceuticals was successfully concluded!

2026-01-01

2026: Steadfast and Unwavering, Moving Forward with Conviction

2025-12-26

Caremo Earns Another Authoritative Endorsement! Proficiency Testing Certificate Demonstrates Solid Bioanalytical Strength!

R&D Service

New Drug Preclinical Research Service

Caremo empowers pharmaceutical companies to identify high-value drug candidates for clinical trials by delivering high-quality data and accelerated timelines. The preclinical research division of Caremo encompasses:

- Target screening and preclinical candidate compound (PCC) identification
- Pharmacology and efficacy studies
- Pharmacokinetics (PK) analysis
- Preliminary toxicology and safety assessments

CMC Service

Caremo is dedicated to delivering high-quality, efficient, and integrated one-stop CMC (Chemical, Manufacturing, and Controls) services. Our offerings include:

- CMC Development for Generic Drugs & Small Molecule Innovative Drugs
- Feasibility Assessment and Project Initiation
- API & Formulation Process Optimization and Development
- Pilot-Scale and Commercial-Scale Production
- Stability Studies
- Clinical Sample Manufacturing (GMP Compliance)

Clinical Research Service

Caremo provides one-stop clinical research services for domestic and international pharmaceutical companies, biotech firms, and medical device enterprises, spanning from preclinical evaluation (Pre-IND application) to post-marketing studies.

Technology Platforms

Caremo has established a shared and collaborative drug R&D technology platform. Simultaneously, we continuously adopt and refine innovative technologies through iterative processes to accelerate drug discovery and development.

Drug solid-state R&D platform

Transdermal drug delivery
system R&D platform

High activity API R&D platform

Oral disintegration R&D platform

Specially targeted drug R&D platform

Fixed dose drug compound
preparation R&D platform

Genotoxic impurity analysis platform

Oral sustained-release drug
preparation R&D platform

Insoluble drug solubilization
R&D platform